[1]徐龙辰,王 葳,潘 婕,等.芪明颗粒治疗糖尿病视网膜病变的成本-效用分析[J].卫生经济研究,2025,42(05):66-69.
　XU Longchen,WANG Wei,PAN Jie,et al.Cost-utility Analysis of Qiming Granule for the Treatment of Diabetic Retinopathy[J].Journal Press of Health Economics Research,2025,42(05):66-69.
点击复制

芪明颗粒治疗糖尿病视网膜病变的成本-效用分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年05期
页码:
66-69
栏目:
成本与费用
出版日期:
2025-04-24

文章信息/Info

Title:
Cost-utility Analysis of Qiming Granule for the Treatment of Diabetic Retinopathy
作者:
徐龙辰1; 王 葳1; 潘 婕2; 朱文涛2; 伍 玲3; 印咪璐4
1.中国航天科工集团七三一医院，北京 100074
2.北京中医药大学，北京 102488
3.浙江省医药行业协会，浙江 杭州 310005
4.浙江三生蔓迪药业有限公司，浙江 杭州 311308
Author(s):
XU Longchen;  WANG Wei;  PAN Jie;  ZHU Wentao;  WU Ling;  YIN Milu
Aerospace 731 Hospital, Beijing 100074, China
关键词:
芪明颗粒; 糖尿病视网膜病变; 成本-效用; Markov模型
Keywords:
Qiming granule;  diabetic retinopathy;  cost-utility;  Markov model
分类号:
R19
文献标志码:
A
摘要:
目的：对芪明颗粒治疗糖尿病视网膜病变的成本-效用进行分析，为中医药治疗糖尿病的经济学评价提供新的案例。方法：以临床研究结果为数据来源，构建Markov模型；以芪明颗粒联合基础治疗为试验组，基础治疗为对照组，对2种治疗方案进行成本-效用分析和敏感性分析。结果：到第25年末，与对照组相比，试验组多获得0.34QALY，多花费11 595.75元，ICER为34 105.15元/QALY；同时，糖尿病患者失明率有所下降。结论：芪明颗粒治疗糖尿病视网膜病变具有经济性。
Abstract:
Objective To analyze the cost-utility of Qiming granule for the treatment of diabetic retinopathy, and to provide a new case for the economic evaluation of traditional Chinese medicine for the treatment of diabetes mellitus. Methods Using the results of clinical studies as the data source, the Markov model was constructed. Cost-utility analysis and sensitivity analysis of the two treatment schemes were performed with Qiming granule combined with basic treatment as the experimental group and basic treatment as the control group. Results By the end of the 25th year, compared with the control group, the experimental group gained 0.34 QALY more and spent 11 595.75 yuan more, with an ICER of 34 105.15 yuan/QALY. At the same time, there was a decrease in the rate of diabetic blindness. Conclusion Qiming granule is economical for the treatment of diabetes retinopathy.

参考文献/References:

[1] 郑雅琴，陈继东，曾明星，等.糖尿病视网膜病变炎症机制与中药提取物干预的研究进展[J].现代中西医结合杂志，2022，31（14）：2029-2035.
[2] Safi H,Safi S,Hafezi-Moghadam A,et al.Early detection of diabetic retinopathy[J].Surv Ophthalmol,2018,63(05):601-608．
[3] 韩晶，武正清.微小RNA表达在糖尿病视网膜病变中的作用研究进展[J].中国现代医药杂志，2016，18（03）：104-108.
[4] Song P,Yu J,Chan K Y,et al.Prevalence,risk factors and burden of diabetic retinopathy in China:a syst ematic review and meta-analysis[J].J Glob Health,2018,8(01):010803.
[5] Liu Y,Song Y,Tao L,et al.Prevalence of diabetic retinopathy among 13 473 patients with diabetes mellitus in China:a cross-sectional epidemiological survey in six provinces[J].BMJ Open,2017,7(01):e013199.
[6] Zhang G H,Chen H Y,Chen W Q,et al.Prevalence and risk factors for diabetic retinopathy in China:a multi-hospital-based cross-sectional study[J].Br J Ophthalmol,2017,101(12):1591-1595.
[7] Teo Z L,Yc T,Yu M,et al.Global prevalence of diabetic retinopathy and projection of burden through 2045:systematic review and meta-analysis[J].Ophthalmology,2021,128(11):1580-1591.
[8] NCD Risk Factor Collaboration．Worldwide trends in diabetes since 1980:a pooled analysis of 751 populationbased studies with 4.4 million participants[J].Lancet,2016,387(10027):1513－1530．
[9] Yau J W,Rogers S L,Kawasaki R Yau,et al．Global prevalence and major risk factors of diabetic retinopathy[J].Diabetes Care,2012,35(03):556－564．
[10] Srikanth P.Using Markov Chains to predict the natural progression of diabetic retinopathy[J].Int J Ophthalmol,2015,18,8(01):132-137.
[11] 中国药学会药物经济学专业委员会.中国药物经济学评价指南（第8稿）[J].中国药物经济学，2010，5（05）：5-43.
[12] Woung L C,Tsai C Y,Chou H K,et al.Healthcare costs associated with progressivediabetic retinopathy among National Health Insurance enrollees in Taiwan,2000-2004[J].BMC Health Services Research,2010,10:136-140.
[13] 段俊国.治疗糖尿病视网膜病变中药新药临床循证研究[C].山东省第十九次眼科学学术会议论文集，2015.
[14] Pesonen M,Kankaanp E,Vottonen P.Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: a markov-model[J].Acta Ophthalmol,2021,99(07):e1146-e1153.
[15] 张洪春，杨道文，崔红生，等.宣肺止嗽合剂对感染后咳嗽（风邪犯肺证）中医证候和生活质量的影响观察：一项随机、安慰剂对照、双盲、多中心临床研究[J].中华中医药学刊，2024，42（07）：1-5.

更新日期/Last Update: 2025-04-24